Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 2Stomach Neoplasms 1Gastrointestinal Neoplasms 1Esophageal 1Carcinoma, Hepatocellular 1Advanced Pancreatic Cancer 1Advanced Gastric Cancer 1Advanced Colorectal Cancer 1

Interventions

Gemcitabine 9130-nm albumin-bound paclitaxel 6S 1 (combination) 4Albumin-Bound Paclitaxel 4toripalimab 3Taxes 3Nivolumab 2Injections 2Drug Therapy 2surufatinib 1penpulimab 1pegylated granulocyte colony-stimulating factor 1paricalcitol 1nimotuzumab 1irinotecan sucrosofate 1gimeracil 1fluzoparib 1envafolimab 1endostar protein 1conteltinib 1camrelizumab 1cabiralizumab 1apatinib 1Tegafur 1Simvastatin 1Radiosurgery 1Paclitaxel 1Oxaliplatin 1Metformin 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Pancreatic Cancer × endostar protein × Gastrointestinal × Clear all
NCT05298020 2022-03-28

Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer

The Affiliated Hospital of Xuzhou Medical University

Phase 2 Unknown
20 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡